| Barchart Demo Center |
$0.96
-0.01 (-1.03%)
as of Jan 21, 2020
as of Jan 21, 2020
| Profile | |
|---|---|
| Ticker Symbol | SESN |
| Exchange | NASDAQ |
| Contact Information |
245 FIRST STREET SUITE 1800 CAMBRIDGE, MA USA P: 617-444-8550 |
| CEO/President | Thomas R. Cannell |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 09/30/19 -0.13 |
06/30/19 -0.67 |
03/31/19 -0.08 |
12/31/18 -0.10 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | -2.70 | |||
| Most Recent Earnings ($) | -0.13 | |||
| Annual EPS ($) | -0.97 | |||
| Business Summary | |
|---|---|
| Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc. formerly known as Eleven Biotherapeutics is based in Massachusetts United States. | |
| Industry/Sector | Information not available. |